Updated on 4 June 2013
Capitalizing on the generics market opportunities in Japan, Lupin's Japanese subsidiary Kyowa Pharmaceutical built a strong presence in neurology, cardiovascular, gastroenterology and the respiratory therapy segments. Over the past five years, Kyowa has registered a growth of 39 percent and contributed 12 percent to Lupin's consolidated revenue.
Strengthening its focus on R&D pipeline, Lupin showed green flag to its asthma research labs in India and initiated 10 new drug discovery research programs. Lupin is developing specialized and complex active pharmaceutical ingredients (APIs) like prostaglandins and hormones for the US, EU, Japan and other advanced markets.